CTBO (Cantabio Pharmaceuticals) Current Accrued Expense: $0.16 Mil (As of Dec. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cantabio Pharmaceuticals Current Accrued Expense?

Cantabio Pharmaceuticals CTBO Current Accrued Expense is $0.16 Mil as of Dec. 2018.

Cantabio Pharmaceuticals's Current Accrued Expense for the quarter that ended in Dec. 2018 was $0.16 Mil.

Cantabio Pharmaceuticals's quarterly Current Accrued Expense increased from Jun. 2018 ($0.16 Mil) to Sep. 2018 ($0.16 Mil) and increased from Sep. 2018 ($0.16 Mil) to Dec. 2018 ($0.16 Mil).

Cantabio Pharmaceuticals's annual Current Accrued Expense declined from Mar. 2016 ($0.17 Mil) to Mar. 2017 ($0.14 Mil) but then increased from Mar. 2017 ($0.14 Mil) to Mar. 2018 ($0.17 Mil).

Cantabio Pharmaceuticals Current Accrued Expense Related Terms

Cantabio Pharmaceuticals Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals Current Accrued Expense Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
Current Accrued Expense
Get a 7-Day Free Trial 0.01 0.22 0.17 0.14 0.17

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.17 0.16 0.16 0.16

Cantabio Pharmaceuticals Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.16 Mil mean?
Cantabio Pharmaceuticals (CTBO) has a Current Accrued Expense of $0.16 Mil as of Dec. 2018. Current Accrued Expense records the total amount of accrued expenses. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' Current Accrued Expense too high?
Cantabio Pharmaceuticals' current Current Accrued Expense is $0.16 Mil.
How does Cantabio Pharmaceuticals' Current Accrued Expense compare to TNTY and ETNI?
Cantabio Pharmaceuticals' Current Accrued Expense of $0.16 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current Current Accrued Expense is $0.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current Current Accrued Expense of $0.16 Mil. The current Current Accrued Expense is $0.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current Current Accrued Expense is $0.16 Mil as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.